Tafamidis for the treatment of transthyretin-associated familial amyloid polyneuropathy

Expert Opinion on Orphan Drugs

Volumn 1, Issue 10, 2013, Pages 837-845

  Schmidt, Hartmut H J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Amyloidosis; Familial amyloid polyneuropathy; Polyneuropathy; Tafamidis; Transthyretin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DIFLUNISAL; DOXYCYCLINE; PLACEBO; PREALBUMIN; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID;

ANALGESIA; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL AMYLOID POLYNEUROPATHY; GLUCURONIDATION; HEALTH CARE QUALITY; HUMAN; LIVER TOXICITY; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROID FUNCTION; TRANSTHYRETIN ASSOCIATED FAMILIAL AMYLOID POLYNEUROPATHY; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VAGINITIS;

EID: 84896734458     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.841576     Document Type: Article

References (49)

1. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-27
2. Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 1978;75:4499-503
3. Mita S, Maeda S, Shimada K, Araki S. Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. J Biochem 1986;100:1215-22
4. Blake CC, Geisow MJ, Oatley SJ, et al. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 1978;121:339-56
5. Hammarstrom P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002;99(Suppl 4):16427-32
6. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30
7. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012;421:185-203
8. Sousa MM, Cardoso I, Fernandes R, et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159:1993-2000
9. Andersson K, Olofsson A, Nielsen EH, et al. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002;294:309-14
10. Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004;101:2817-22
11. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086-97
12. ORPHANET. Prevalence of rare diseases: Bibliographic data. 12 A.D. Nov. Report No.: 1
13. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-84
14. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8
15. Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003;60:1625-30
16. Levy J, Hawkins PN, Rowczenio D, et al. Familial amyloid polyneuropathy associated with the novel transthyretin variant Arg34Gly. Amyloid 2012;19:201-3
17. Benson MD, Cohen AS. Generalized amyloid in a family of Swedish origin. A study of 426 family members in seven generations of a new kinship with neuropathy, nephropathy, and central nervous system involvement. Ann Intern Med 1977;86:419-24
18. Tawara S, Nakazato M, Kangawa K, et al. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983;116:880-8
19. Holmgren G, Holmberg E, Lindstrom A, et al. Diagnosis of familial amyloidotic polyneuropathy in Sweden by RFLP analysis. Clin Genet 1988;33:176-80
20. Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995;60:512-21
21. Plante-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003;40:e120
22. Coutinho P, Da Silva AM, Lima JL, Barbosa AR. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG, Costa PP, Falcao de Freitas A, editors. Amyloid and Amyloidosis. amsterdam; 1980. p. 88-98
23. Conceicao I. Clinical features of TTR-FAP in Portugal. Amyloid 2012;19(Suppl 1):71-2
24. Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351-4
25. Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-6
26. Jacobson DR, Gertz MA, Buxbaum JN. Transthyretin VAL107, a new variant associated with familial cardiac and neuropathic amyloidosis. Hum Mutat 1994;3:399-401
27. Plante-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007;69:693-8
28. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAPmet30). Clin Genet 1991;40:242-6
29. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71
30. Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid 2005;12:233-8
31. Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012;78:637-43
32. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123(Pt 7):1495-504
33. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007;14:277-82
34. Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007;7:235-42
35. Ihse E, Suhr OB, Hellman U, Westermark P. Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) 2011;89:171-80
36. Berk JL, Suhr OB, Sekijima Y, et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid 2012;19(Suppl 1):37-8
37. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012;101:805-13
38. Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 2013;6:129-39
39. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012;19(Suppl 1):43-4
40. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19(Suppl 1):34-6
41. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109:9629-34
42. Coelho T, Maia LF, Martins da SA, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785-92
43. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus Report of the European Assessment. Ann Neurol 1995;38:478-82
44. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229-39
45. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284:2215-21
46. Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005;7:497-508
47. European Medicines Agency (EMA). Vyndaqel (R) Assessment Report. 2011
48. Lozeron P, Theaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 2013
49. Plante-Bordeneuve V, Suhr OB, Maurer MS, et al. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 2013;29:77-84